Shares of Bruker Corporation (NASDAQ:BRKR) have been given a consensus recommendation of “Hold” by the fourteen analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $27.00.

Several research analysts recently weighed in on BRKR shares. Cowen and Company reissued a “hold” rating and issued a $29.00 target price on shares of Bruker Corporation in a research note on Friday, July 14th. Zacks Investment Research raised shares of Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research note on Thursday, July 6th. Barclays PLC reissued an “equal weight” rating and issued a $30.00 target price (up previously from $26.00) on shares of Bruker Corporation in a research note on Monday, July 17th. Wells Fargo & Company downgraded shares of Bruker Corporation from a “market perform” rating to an “underperform” rating in a research note on Wednesday, July 12th. Finally, BidaskClub downgraded shares of Bruker Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th.

In other news, CEO Frank H. Laukien bought 2,335 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was acquired at an average price of $27.39 per share, for a total transaction of $63,955.65. Following the acquisition, the chief executive officer now owns 37,791,386 shares of the company’s stock, valued at $1,035,106,062.54. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Mark Munch sold 21,061 shares of the business’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total value of $631,198.17. Following the sale, the vice president now owns 60,524 shares of the company’s stock, valued at approximately $1,813,904.28. The disclosure for this sale can be found here. 35.20% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the company. Acrospire Investment Management LLC grew its holdings in shares of Bruker Corporation by 496.1% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock worth $110,000 after purchasing an additional 3,185 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Bruker Corporation during the 2nd quarter worth about $111,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Bruker Corporation by 11.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock worth $133,000 after purchasing an additional 467 shares during the period. Smithfield Trust Co. purchased a new stake in shares of Bruker Corporation during the 2nd quarter worth about $138,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Bruker Corporation by 7.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock worth $144,000 after purchasing an additional 331 shares during the period. Institutional investors and hedge funds own 65.42% of the company’s stock.

Shares of Bruker Corporation (NASDAQ BRKR) traded down 0.80% during midday trading on Friday, hitting $29.85. 692,195 shares of the company were exchanged. Bruker Corporation has a 52-week low of $19.59 and a 52-week high of $30.22. The company has a 50-day moving average price of $28.49 and a 200-day moving average price of $26.46. The stock has a market capitalization of $4.74 billion, a price-to-earnings ratio of 29.76 and a beta of 1.10.

Bruker Corporation (NASDAQ:BRKR) last announced its earnings results on Thursday, August 3rd. The medical research company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.03. Bruker Corporation had a net margin of 9.65% and a return on equity of 26.66%. The firm had revenue of $414.90 million during the quarter, compared to the consensus estimate of $384.75 million. During the same quarter in the previous year, the company posted $0.20 EPS. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. On average, analysts forecast that Bruker Corporation will post $1.12 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 22nd. Stockholders of record on Tuesday, September 5th will be paid a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.54%. The ex-dividend date is Thursday, August 31st. Bruker Corporation’s dividend payout ratio is currently 16.00%.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/16/bruker-corporation-brkr-receives-consensus-recommendation-of-hold-from-brokerages.html.

About Bruker Corporation

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.